Remarks

Reconsideration of this Application is respectfully requested.

Upon entry of the foregoing amendment, claims 41-59 are pending in the application with claim 41 being the independent claim. Applicants have cancelled claims 1-40 without prejudice to or disclaimer of the subject matter therein. A table showing examples of support for newly added claims 41-59 is attached (Table 1). These changes are believed to introduce no new matter, and their entry is respectfully requested.

The specification has also been amended to perfect the priority claim. Support for the incorporation by reference of the priority applications may be found in the original specification in the paragraph beginning at page 1, line 8.

The paragraph in the specification at page 13, line 18 has also been amended. Support for the language in the paragraph can be found in priority Application No. 08/103,396, filed August 6, 1993, and incorporated by reference in the originally filed application.

Conclusion

Consideration of this Amendment is respectfully requested. Applicants respectfully submit that the application is in proper condition for allowance.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Peter A. Jackman

Attorney for Applicants Registration No. 45,986

Date:) 1 22, 2002

1100 New York Avenue, N.W. Washington, D.C. 20005-3934 (202) 371-2600

SKGF_DC1:204674.1

Table 1- Example of Support for Claims

Claim Language	This Application	Appl. No. 08/103,396
T helper peptide	p. 50, line 20 through p. 51, line 12	p.22, lines 18-33
Spacer or linker	p. 50, lines 11-19	p.22, lines 21-36; p.24, lines 34-38
Carrier	p. 42, lines 27-30	p.29, lines 27-38
Lipid	p. 51, lines 15-30	p.23, lines 1-16
Fusion protein	p. 38, lines 22-28	p. 24, lines 25-28
Liposome	p. 51, lines 25-30; p.55, line 25 through p. 56, line 7	p.28, lines 1-26
Homopolymer/ heteropolymer	p. 42, lines 27-30	p.29, lines 27-29
Less than 15 amino acids in length	p. 13, lines 21-23, as amended	p.4, line 15
8, 9, 10, or 11 amino acids in length	p. 13, lines 21-23	p.4, lines 16-17